Results 121 to 130 of about 9,543 (166)

Low BMD is uncommon in pediatric mastocytosis: a DEXA- based cohort study. [PDF]

Eur J Pediatr
Geypen A, Jhinkoe C, Pasmans SGMA, Arends NJT.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cutaneous mastocytosis: A dermatological perspective

Australasian Journal of Dermatology, 2020
AbstractMastocytosis is a rare disease characterised by expansion and collection of clonal mast cells in various organs including the skin, bone marrow, spleen, lymph nodes and gastrointestinal tract. The prevalence of mastocytosis has been estimated to be one in 10 000, while the estimated incidence is one per 100 000 people per year.
Di Raimondo, Cosimo, Del Duca, Ester, Silvaggio, Dionisio, Di Prete, Monia, Lombardo, Paolo, Mazzeo, Mauro, Spallone, Giulia, Campione, Elena, Botti, Elisabetta, Bianchi, Luca   +9 more
openaire   +5 more sources

Familial Cutaneous Mastocytosis

Pediatric Dermatology, 2001
Cutaneous mastocytosis appears to occur sporadically; however, familial inheritance has been reported in 50 families since the mid‐1880s. We report four cases of telangiectasia macularis eruptiva perstans (TMEP) occurring in three generations of a family. Whereas most patients with TMEP manifest in adulthood, all of the members of this family developed
A, Chang, R C, Tung, T, Schlesinger, W F, Bergfeld, J, Dijkstra, T A, Kahn   +5 more
openaire   +2 more sources

Equine Cutaneous Mastocytosis

Pathologia veterinaria, 1970
A description of equine cutaneous mastocytosis is given. The lesion was characterized by focal aggregates of mast cells, and by eosinophils, fibrinoid necrosis of collagen, and focal necrosis with dystrophic mineralization of necrotic debris. This is an uncommon, previously undescribed lesion in horses.
K, Altera, L, Clark
openaire   +2 more sources

Treatment of Cutaneous Mastocytosis

International Archives of Allergy and Immunology, 2002
Therapy of cutaneous mastocytosis is directed towards skin and systemic symptoms due to mediator release and targeted on skin lesions. Symptomatic therapy of cutaneous mastocytosis involves agents that inhibit the release of mediators or antagonize H1 and H2 receptors such as antihistamines ketodifen and Aspirin.
openaire   +2 more sources

Challenges in Cutaneous Mastocytosis

Immunology and Allergy Clinics of North America
Cutaneous lesions of mastocytosis (CLM) are a hallmark for the diagnosis of mastocytosis. The nomenclature of the term "cutaneous mastocytosis" (CM) is ambiguous as it is used both for classification excluding and as a morphologic description including systemic variants of mastocytosis.
Franz, Tobias, Hubbuch, Mara, Rupp, Svenja, Brockow, Knut   +3 more
openaire   +3 more sources

Atypical Diffuse Cutaneous Mastocytosis

Archives of Pediatrics & Adolescent Medicine, 1972
A 19-month-old boy was found to have atypical diffuse cutaneous mastocytosis. Although severe dermographism and pressure urticaria were present from early infancy, his disease remained undiagnosed because he lacked the characteristic bullous and pigmented lesions of urticaria pigmentosa and the pebbly skin texture usually found in diffuse cutaneous ...
T, Sahihi, N B, Esterly
openaire   +2 more sources

Dermatoscopic Findings of Cutaneous Mastocytosis

Dermatology, 2008
<i>Background:</i> Mastocytosis is a disorder characterized by the accumulation of mast cells in various organs, most commonly in the skin. Cutaneous mastocytosis (CM) can be classified as nodular CM with solitary or multiple lesions, diffuse CM (erythroderma), and maculopapular CM including the papular/plaque variant, urticaria pigmentosa (
Bengü Nisa, Akay, Harald, Kittler, Hatice, Sanli, Kaan, Harmankaya, Rana, Anadolu   +4 more
openaire   +2 more sources

Cutaneous Mastocytosis – Clinical Heterogeneity

International Archives of Allergy and Immunology, 2002
Cutaneous mastocytosis (CM) encompasses several distinct patterns of disease which can be distinguished by the type of skin lesions, age of onset, familial occurrence, noncutaneous involvement, associated c-kit mutations, and prognosis. A clear distinction of the type of CM in individual patients has important implications regarding patient management ...
Hartmann, Karin, Henz, Beate M.
openaire   +3 more sources